C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
There is increasing evidence for the role of inflammation in schizophrenia, yet the stability of increased peripheral inflammation in acute psychosis and the degree to which peripheral inflammation relates to cortical thickness, a measure of the degree of neuropathology, are unknown. In independent samples, we assessed the peripheral inflammation marker C-reactive protein (CRP) to determine the extent to which: (1) CRP was elevated and stable across admissions for acute psychosis, (2) cognition, daily function and symptom severity are characteristic of chronically ill patients with schizophrenia displaying elevated CRP, and (3) CRP levels predict cortical thickness. Study 1 assessed peripheral CRP (primary outcome) and other blood measures in 174/280 people with acute psychosis while Study 2 assessed peripheral CRP, cognition and cortical thickness (primary outcomes), symptoms, and daily function in 85/97 chronically ill patients with schizophrenia and 71/87 healthy controls. In acute psychosis, CRP and neutrophil-to-lymphocyte ratio were significantly elevated relative to a normal cutoff (with 59.8% of patients having elevated CRP) which remained elevated across admissions. CRP was significantly elevated in 43% of chronically ill patients with schizophrenia compared to 20% in controls. Elevated CRP patients displayed significantly worse working memory and CRP was inversely correlated with cortical thickness in frontal, insula, and temporal brain regions. This work supports the role of inflammation in psychotic illnesses and suggests that use of peripheral markers (e.g., CRP) in conjunction with diagnosis could be used to identify patients with more cortical neuropathology and cognitive deficits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Henry, J. D., & Crawford, J. R. (2005) · British Journal of Clinical Psychology · doi:10.1348/014466505x29657 · Cited by 5,801 · cited 1×
“Negative emotional states, daily function and quality of life were assessed with the 21-item version of the Depression, Anxiety and Stress Scale (DASS-21) (65), the Short Form 36 Version 2 Health Survey Questionnaire (SF-36v2) (66), and the Schizophrenia Quality of Life Scale (SQLS) (67), respectively.”
MethodC-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742 · cited 1×
“These findings are consistent with metaanalytical results showing that cytokines are increased in the serum of people with schizophrenia (31).”
ResultPrenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies
Brown, A. S., & Derkits, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030361 · Cited by 1,269
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010 · cited 1×
“The healthy normal clinical range of CRP levels is generally < 3 mg/L (36), whilst CRP > 2 mg/L has been associated with increased risk of cardiovascular disease (37).”
BackgroundInflammatory markers and cognition in well-functioning African-American and white elders
Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S., & Harris, T. (2003) · Neurology · doi:10.1212/01.wnl.0000073620.42047.d7 · Cited by 706 · cited 1×
“Some studies have shown that elevated CRP is associated with poorer cognitive performance (verbal memory, global cognition) both in patients with schizophrenia (40) and healthy older adults (70).”
BackgroundFillman, S. G., Cloonan, N., Catts, V. S., Miller, L. C., Wong, J., McCrossin, T., Cairns, M., & Weickert, C. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.110 · Cited by 609 · cited 2×
“This is consistent with our report of a similar proportion (∼40%) of chronically ill patients displaying elevated cytokine mRNA expression in post-mortem prefrontal cortex tissue (17) and displaying elevated cytokine mRNA expression in blood (69).”
BackgroundResultSelf-citationCannon, T. D., Chung, Y., He, G., Sun, D., Jacobson, A., van Erp, T. G. M., McEwen, S., Addington, J., Bearden, C. E., Cadenhead, K., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.023 · Cited by 599 · cited 1×
“Increases in inflammatory markers have been shown in subsets of individuals in both the prodromal stage (27, 28) and firstepisode psychosis (29), suggesting that inflammation is not secondary to chronic illness or initiation of antipsychotics.”
Background
Research works printed but not linked: 64
- American, 2013, Diagnostic and Statistical Manual of Mental Disorders.
- Weickert, 2013, Biomarkers in schizophrenia: A brief conceptual consideration, Dis Markers, 35, 3, 10.1155/2013/510402 · DOI
- Weickert, 2016, What's hot in schizophrenia research?, Psychiatr Clin North Am, 39, 343, 10.1016/j.psc.2016.01.011 · DOI
- Gibney, 2013, Evidence for a dysregulated immune system in the etiology of psychiatric disorders, J Neuroimmune Pharmacol, 8, 900, 10.1007/s11481-013-9462-8 · DOI · Paper page
- Horvath, 2014, Immune system disturbances in schizophrenia, Biol Psychiatry, 75, 316, 10.1016/j.biopsych.2013.06.010 · DOI · Paper page
- Muller, 2014, Immunology of schizophrenia, Neuroimmunomodulation, 21, 109, 10.1159/000356538 · DOI · Paper page
- Benros, 2014, A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis, Am J Psychiatry, 171, 218, 10.1176/appi.ajp.2013.13010086 · DOI · Paper page
- Chen, 2012, Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study, Br J Psychiatry, 200, 374, 10.1192/bjp.bp.111.092098 · DOI · Paper page
- Cazzullo, 2002, Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study, Prog Neuropsychopharmacol Biol Psychiatry, 26, 33, 10.1016/S0278-5846(01)00221-4 · DOI
- Zhang, 2004, Changes in serum interleukin-2,−6, and−8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia, J Clin Psychiatry, 65, 940, 10.4088/JCP.v65n0710 · DOI · Paper page
- Meyer, 2009, Inflammatory markers in schizophrenia: comparing antipsychotic effects in Phase 1 of the CATIE Schizophrenia Trial, Biol Psychiatry, 66, 1013, 10.1016/j.biopsych.2009.06.005 · DOI · Paper page
- Laan, 2010, Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, 71, 520, 10.4088/JCP.09m05117yel · DOI · Paper page
- Muller, 2002, Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia, Am J Psychiatry, 159, 1029, 10.1176/appi.ajp.159.6.1029 · DOI · Paper page
- Chaudhry, 2012, Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment, J Psychopharmacol, 26, 1185, 10.1177/0269881112444941 · DOI · Paper page
- Potvin, 2008, Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review, Biol Psychiatry, 63, 801, 10.1016/j.biopsych.2007.09.024 · DOI · Paper page
- Volk, 2015, Molecular mechanisms and timing of cortical immune activation in schizophrenia, Am J Psychiatry, 172, 1112, 10.1176/appi.ajp.2015.15010019 · DOI · Paper page
- Miller, 2013, Total and differential white blood cell counts, high-sensitivity C-reactive protien, and the metabolic syndrome in non-affective psychoses, Brain Behav Immun, 31, 82, 10.1016/j.bbi.2012.08.016 · DOI · Paper page
- Schott, 1996, Antinuclear antibodies in schizophrenia and major depressive disorder - A lasting puzzle, Eur Psychiatry, 11, 263, 10.1016/0924-9338(96)82334-0 · doi:10.1016/0924-9338(96)82334-0
- Spivak, 1995, Antinuclear autoantibodies in chronic schizophrenia, Acta Psychiatr Scand, 92, 266, 10.1111/j.1600-0447.1995.tb09581.x · DOI
- Kulaksizoglu, 2016, Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia, Neuropsychiatr Dis Treat, 12, 1999, 10.2147/NDT.S110484 · DOI · Paper page
- Semiz, 2014, Elevated neutrophil/lymphocyte ratio in patients with schizophrenia, Psychiatr Danub, 26, 220
- Singh, 2014, Role of C-reactive protein in schizophrenia: an overview, Psychiatry Res, 216, 277, 10.1016/j.psychres.2014.02.004 · DOI
- Zajkowska, 2014, First-episode psychosis: an inflammatory state?, Neuroimmunomodulation, 21, 102, 10.1159/000356536 · DOI · Paper page
- Deodhar, 1989, C-reactive protein: the best laboratory indicatory available for monitoring disease activity, Cleve Clin J Med, 56, 126, 10.3949/ccjm.56.2.126 · DOI · Paper page
- Libby, 2004, Inflammation and atherosclerosis: role of C-reactive protein in risk assessment, Am J Med, 116, 9, 10.1016/j.amjmed.2004.02.006 · DOI · Paper page
- Tsimikas, 2006, C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients, J Am Coll Cardiol, 47, C19, 10.1016/j.jacc.2005.10.066 · DOI · Paper page
- Miller, 2014, C-Reactive protein levels in schizophrenia: a review and meta-analysis, Clin Schizophr Relat Psychoses, 7, 223, 10.3371/CSRP.MICU.020813 · DOI · Paper page
- Metcalf, 2017, Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: a prospective birth cohort study, Brain Behav Immun, 59, 253, 10.1016/j.bbi.2016.09.008 · DOI · Paper page
- Bulzacka, 2016, Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset, Schizophr Bull, 42, 1290, 10.1093/schbul/sbw029 · DOI · Paper page
- Dickerson, 2007, C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia, Schizophr Res, 93, 261, 10.1016/j.schres.2007.03.022 · DOI · Paper page
- Johnsen, 2016, The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis, BMC Psychiatry, 16, 1, 10.1186/s12888-016-0769-x · DOI
- Fan, 2007, Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia, Psychiatry Res, 149, 267, 10.1016/j.psychres.2006.07.011 · DOI · Paper page
- Solanki, 2009, C-reactive protein (CRP) in patients with schizophrenia: are they related with symptomatology?, J Mental Health Hum Behav., 15, 6
- Mazzarello, 2004, Lymphocytes in schizophrenia patients under therapy: serological, morphological and cell subset findings, Ital J Anat Embryol, 109, 177
- Ohaeri, 1993, The profile of C-reactive proteins in functional psychotic states in a cohort in Nigeria, Acta Psychiatr Scand, 88, 252, 10.1111/j.1600-0447.1993.tb03452.x · doi:10.1111/j.1600-0447.1993.tb03452.x
- Bettcher, 2012, C-reactive protein is related to memory and medial temporal brain volume in older adults, Brain Behav Immun, 26, 103, 10.1016/j.bbi.2011.07.240 · DOI · Paper page
- Taki, 2013, Correlation between high-sensitivity C-reactive protein and brain gray matter volume in healthy elderly subjects, Hum Brain Mapp, 34, 2418, 10.1002/hbm.22073 · DOI
- Wing, 1998, Health of the Nation Outcome Scales (HoNOS), Br J Psychiatry, 172, 11, 10.1192/bjp.172.1.11 · DOI · Paper page
- Woods, 2003, Chlorpromazine equivalent doses for the newer atypical antipsychotics, J Clin Psychiatry, 64, 663, 10.4088/JCP.v64n0607 · DOI · Paper page
- Cohen, 1988, Statistical Power Analysis for the Behavioral Sciences.
- Shcherbakova, 1999, The possible role of plasma kallikrein-kinin system and leukocyte elastase in the pathogenesis of schizophrenia, Immunopharmacology, 43, 273, 10.1016/S0162-3109(99)00099-5 · DOI
- Barzilay, 2016, Elevated C-reactive protein in schizophrenia inpatients is associated with aggressive behavior, Eur Psychiatry, 31, 8, 10.1016/j.eurpsy.2015.09.461 · DOI · Paper page
- Raj, 2013, Antinuclear antibodies in general population: what does that mean?, J Immunol, 190, 197, 10.4049/jimmunol.190.Supp.197.2 · doi:10.4049/jimmunol.190.supp.197.2
- Yamada, 2001, Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: jichi medical school cohort study, Am J Epidemiol, 153, 1183, 10.1093/aje/153.12.1183 · DOI · Paper page
- Costello, 2013, C-reactive protein and substance use disorders in adolescence and early adulthood: a prospective analysis, Drug Alcohol Depend, 133, 712, 10.1016/j.drugalcdep.2013.08.027 · DOI · Paper page
- O'Loughlin, 2008, Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents, Nicotine Tob Res, 10, 525, 10.1080/14622200801901997 · DOI · Paper page
- Weickert, 2015, Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia, Mol Psychiatry, 20, 685, 10.1038/mp.2015.11 · DOI
- First, 2002, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition
- Wechsler, 1997, Wechsler Adult Intelligence Scale
- Wechsler, 2001, Wechsler Test of Adult Reading
- Lezak, 2004, Neuropsychological Assessment.
- Reitan, 1985, The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation
- Wechsler, 1987, Wechsler Memory Scale - Revised
- Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
- Ware, 2000, SF-36 Health Survey: Manual and Interpretation Guide
- Wilkinson, 2000, Self-report quality of life measure for people with schizophrenia: the SQLS, Br J Psychiatry, 177, 42, 10.1192/bjp.177.1.42 · DOI · Paper page
- Boerrigter, 2017, Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder, J Neuroinflammation, 10.1186/s12974-017-0962-y · DOI · Paper page
- Callicott, 2003, Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down, Am J Psychiatry, 160, 2209, 10.1176/appi.ajp.160.12.2209 · DOI · Paper page
- Soufer, 1998, Cerebral cortical hyperactivation in response to mental stress in patients with cornary artery disease, Proc Natl Acad Sci USA, 95, 6454, 10.1073/pnas.95.11.6454 · DOI · Paper page
- Barbour, 2017, Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013-2015, Morb Mortal Wkly Rep., 66, 246, 10.15585/mmwr.mm6609e1 · DOI · Paper page
- Gunstad, 2006, C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease, J Clin Neurosci, 13, 540, 10.1016/j.jocn.2005.08.010 · DOI
- Gozal, 2007, C-reactive protein, obstructive sleep apnea, and cognitive dysfunction in school-aged children, Am J Respir Crit Care Med, 176, 188, 10.1164/rccm.200610-1519OC · DOI · Paper page
- Trollor, 2010, Systemic inflammation is associated with MCI and its subtypes: the Sydney memory and aging study, Dement Geriatr Cogn Disord, 30, 569, 10.1159/000322092 · DOI · Paper page
- Mansur, 2012, Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages, Psychiatry Clin Neurosci, 66, 247, 10.1111/j.1440-1819.2012.02354.x · DOI
Cited by
Neutrophil-lymphocyte ratios as inflammatory biomarkers in psychiatric patients
Bhikram, T., & Sandor, P. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.07.006 · Cited by 103
Fusar-Poli, L., Natale, A., Amerio, A., Cimpoesu, P., Grimaldi Filioli, P., Aguglia, E., Amore, M., Serafini, G., & Aguglia, A. (2021) · Brain Sciences · doi:10.3390/brainsci11010058 · Cited by 93
Dionisie, V., Filip, G. A., Manea, M. C., Movileanu, R. C., Moisa, E., Manea, M., Riga, S., & Ciobanu, A. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091924 · Cited by 82
Bulut, N. S., Yorguner, N., & Çarkaxhiu Bulut, G. (2021) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2021.1919201 · Cited by 63
Kose, M., Pariante, C. M., Dazzan, P., & Mondelli, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.612471 · Cited by 61
Zulfic, Z., Weickert, C. S., Weickert, T. W., Liu, D., Myles, N., & Galletly, C. (2020) · Australasian Psychiatry · doi:10.1177/1039856220908172 · Cited by 54
Self-citationQuidé, Y., Bortolasci, C. C., Spolding, B., Kidnapillai, S., Watkeys, O. J., Cohen-Woods, S., Carr, V. J., Berk, M., Walder, K., & Green, M. J. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110013 · Cited by 44
Kulacaoglu, F., Yıldırım, Y. E., Aslan, M., & İzci, F. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2116106 · Cited by 18
Metadata
- Authors
- Jacomb, I., Stanton, C., Vasudevan, R., Powell, H., O'Donnell, M., Lenroot, R., Bruggemann, J., Balzan, R., Galletly, C., Liu, D., Weickert, C. S., & Weickert, T. W.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-10
- Volume
- 9
- Pages
- 2230-2230
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2896161650
- Cited by
- 110
- References
- 15
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Health and Medical Research Council (568807)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.